Realcan Pharmaceutical Group (002589.SZ) released its performance for the first three quarters, with a net profit of 19.22 million yuan, a decrease of 68.54%.

Realcan Pharmaceutical Group (002589.SZ) released its third quarter report for 2023. The company's operating income for the first three quarters was 6.105 billion yuan, a decrease of 43.97% compared to the same period last year. The net profit attributable to the shareholders of the listed company was 19.22 million yuan, a decrease of 68.54% compared to the same period last year. The net loss attributable to the shareholders of the listed company, excluding non-recurring gains and losses, was 105 million yuan. The basic earnings per share were 0.0128 yuan.